REGN Investor Alert: Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc.

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is alerting investors that a class action lawsuit has been initiated against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") under NASDAQ: REGN, alongside some of its officials.

Class Action Overview

This lawsuit aims to recover damages for alleged breaches of federal securities laws on behalf of individuals and entities that acquired Regeneron securities from November 2, 2023, to October 30, 2024 (inclusive), referred to as the "Class Period." Affected investors are encouraged to participate in this case by visiting the firm's official website: bgandg.com/REGN.

Details of the Case

The complaint asserts that during the Class Period, the defendants provided misleading information concerning possible infractions of the False Claims Act. Specifically, they allegedly failed to disclose significant discounts given to drug distributors that resulted from reimbursed credit card fees.

Next Steps for Investors

A class action lawsuit has already been filed. Interested parties can review the full Complaint at bgandg.com/REGN. Alternatively, investors may reach out to Peretz Bronstein, Esq., or Nathan Miller, Client Relations Manager, at Bronstein, Gewirtz & Grossman, LLC, by calling 332-239-2660. Investors who experienced losses in Regeneron have until March 10, 2025, to submit a request to be designated as the lead plaintiff. Notably, participating in the recovery does not require serving as the lead plaintiff.

No Financial Obligation for Participants

Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee arrangement for class action cases. This means that legal fees and court-related expenses will only be claimed if the firm successfully recovers funds.

Why Choose Bronstein, Gewirtz & Grossman?

This well-regarded firm specializes in representing investors in cases of securities fraud and shareholder derivative actions. With a strong track record, they have successfully recovered hundreds of millions of dollars for investors throughout the country.

Stay Updated

For ongoing information, follow the firm on LinkedIn, Twitter, Facebook, and Instagram.

Attorney advertising. Previous successes do not guarantee future results.

Contact Information

For any inquiries, reach out to:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 |

[email protected]

lawsuit, investors, Regeneron